Pharming Group (PHAR) to Release Earnings on Thursday

Pharming Group (NASDAQ:PHAR) is expected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $111.7590 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 1:30 PM ET.

Pharming Group Stock Performance

NASDAQ PHAR opened at $16.22 on Thursday. The firm has a market cap of $1.14 billion, a P/E ratio of -1,620.38 and a beta of 0.04. Pharming Group has a 52-week low of $7.50 and a 52-week high of $21.34. The business’s 50-day moving average price is $17.46 and its 200 day moving average price is $15.95. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Zacks Research cut Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. Finally, Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a report on Saturday, December 27th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.00.

Hedge Funds Weigh In On Pharming Group

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC purchased a new position in shares of Pharming Group in the 2nd quarter valued at about $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group during the fourth quarter worth about $224,000. Millennium Management LLC purchased a new position in Pharming Group in the fourth quarter valued at about $360,000. Finally, NewEdge Advisors LLC lifted its position in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares during the period. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.